文献速递神经免疫

EB病毒肽库的血清学反应与多发性硬化风险

Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis.
PubMed 文献 · JAMA Neurol · 2024-01-01

这项前瞻性巢式病例对照研究纳入美国军人30例多发性硬化患者与30名匹配对照,采用VirScan检测2263个EBV肽段抗体。多发性硬化患者对66个EBV肽段(多位于EBNA抗原)抗体反应显著更高,最高三分位与最低三分位相比RR为33.4。调整总抗EBNA-1抗体后多数关联减弱。

要点

  • 多发性硬化患者对66个EBV肽段抗体反应显著更高,多数位于EBNA抗原。
  • 最高三分位与最低三分位抗体富集相比,多发性硬化风险RR为33.4(95%CI 2.5-448.4)。
  • 调整总抗EBNA-1抗体后多数EBV肽段关联减弱,仅4个仍显著关联。

核心结论

  • 这些发现提示对EBNA-1的抗体反应可能是多发性硬化最强的血清学风险因素。
  • 没有单个EBV肽段在多发性硬化患者中呈现选择性靶向而对照中无此现象。
  • 需要更大规模研究来探索多发性硬化中抗EBV体液免疫可能的异质性。

研究设计与样本

  • 前瞻性巢式病例对照研究,样本来自美国国防部血清库存储的军人血清。
  • 多发性硬化患者血清采集于发病前中位1年(2000-2011年报告至军方),并按年龄、性别、种族和族裔、采血时间及军种与对照匹配。
  • 共纳入30例多发性硬化患者与30名对照,平均(SD)采血年龄27.8(6.5)岁,60名参与者中46名(76.7%)为男性。
  • 暴露为采用VirScan(噬菌体展示免疫沉淀测序)检测的人病毒组抗体富集z评分。
  • 数据分析时间为2022年9月1日至2023年8月31日。

主要发现

  • 多发性硬化患者对EBV肽库的抗体反应更强,但无可辨认的模式。
  • 对66个EBV肽段的抗体反应在多发性硬化患者发病前血清中显著更高,多数位于EBNA抗原;最高三分位与最低三分位抗体富集相比RR为33.4(95%CI 2.5-448.4,趋势P=0.008)。
  • 总抗EBNA-1抗体更高也与多发性硬化风险升高相关(最高三分位与最低三分位相比RR为27.6,95%CI 2.3-327.6,趋势P=0.008)。
  • 调整总抗EBNA-1抗体后,大多数EBV肽段分析的风险估计减弱,4个仍与多发性硬化显著相关,最强位于EBNA-6/EBNA-3C,而总抗EBNA-1抗体与多发性硬化的关联持续存在。

局限性

  • 需要更大规模研究来探索多发性硬化中抗EBV体液免疫可能的异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It remains unclear why only a small proportion of individuals infected with the Epstein-Barr virus (EBV) develop multiple sclerosis (MS) and what the underlying mechanisms are. OBJECTIVE: To assess the serologic response to all EBV peptides before the first symptoms of MS occur, determine whether the disease is associated with a distinct immune response to EBV, and evaluate whether specific EBV epitopes drive this response. DESIGN, SETTING, AND PARTICIPANTS: In this prospective, nested case-control study, individuals were selected among US military personnel with serum samples stored in the US Department of Defense Serum Repository. Individuals with MS had serum collected at a median 1 year before onset (reported to the military in 2000-2011) and were matched to controls for age, sex, race and ethnicity, blood collection, and military branch. No individuals were excluded. The data were analyzed between September 1, 2022, and August 31, 2023. EXPOSURE: Antibodies (enrichment z scores) to the human virome measured using VirScan (phage-displayed immunoprecipitation and sequencing). MAIN OUTCOME AND MEASURE: Rate ratios (RRs) for MS for antibodies to 2263 EBV peptides (the EBV peptidome) were estimated using conditional logistic regression, adjusting for total anti-EBV nuclear antigen 1 (EBNA-1) antibodies, which have consistently been associated with a higher MS risk. The role of antibodies against other viral peptides was also explored. RESULTS: A total of 30 individuals with MS were matched with 30 controls. Mean (SD) age at sample collection was 27.8 (6.5) years; 46 of 60 participants (76.7%) were male. The antibody response to the EBV peptidome was stronger in individuals with MS, but without a discernible pattern. The antibody responses to 66 EBV peptides, the majority mapping to EBNA antigens, were significantly higher in preonset sera from individuals with MS (RR of highest vs lowest tertile of antibody enrichment, 33.4; 95% CI, 2.5-448.4; P for trend = .008). Higher total anti-EBNA-1 antibodies were also associated with an elevated MS risk (top vs bottom tertile: RR, 27.6; 95% CI, 2.3-327.6; P for trend = .008). After adjusting for total anti-EBNA-1 antibodies, risk estimates from most EBV peptides analyses were attenuated, with 4 remaining significantly associated with MS, the strongest within EBNA-6/EBNA-3C, while the association between total anti-EBNA-1 antibodies and MS persisted. CONCLUSION AND RELEVANCE: These findings suggest that antibody response to EBNA-1 may be the strongest serologic risk factor for MS. No single EBV peptide stood out as being selectively targeted in individuals with MS but not controls. Larger investigations are needed to explore possible heterogeneity of anti-EBV humoral immunity in MS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Cortese M, Leng Y, Bjornevik K, et al. Serologic Response to the Epstein-Barr Virus Peptidome and the Risk for Multiple Sclerosis. JAMA Neurol. 2024. PMID: 38497939. doi:10.1001/jamaneurol.2024.0272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。